Crizotinib. ALK/Met inhibitor, oncolytic

T. Nwizu, R. Kanteti, Ichiro Kawada, C. Rolle, E. E. Vokes, R. Salgia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

There are a number of molecular abnormalities that can occur in normal cells to induce a malignant phenotype. Recently, the tyrosine kinase receptor anaplastic lymphoma kinase (ALK) has been shown to have gain of function when partnered with different proteins. As an example, on chromosome 2p, with inversion, there is translocation with generation of fusion protein EML4-ALK in lung cancer. In a phase I trial, EML4-ALK-positive patients were selected to determine the response to a potent, small-molecule tyrosine kinase inhibitor, crizotinib (PF-02341066). Marked durable responses were observed with crizotinib 250 mg p.o. twice a day. Interestingly, crizotinib also has activity against tyrosine-protein kinase Met. We have previously shown that Met can be overexpressed, sometimes mutated, or sometimes amplified in lung cancer. Thus, this review will emphasize the characteristics of crizotinib and detail the clinical experience.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalDrugs of the Future
Volume36
Issue number2
DOIs
Publication statusPublished - 2011
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Crizotinib. ALK/Met inhibitor, oncolytic'. Together they form a unique fingerprint.

  • Cite this

    Nwizu, T., Kanteti, R., Kawada, I., Rolle, C., Vokes, E. E., & Salgia, R. (2011). Crizotinib. ALK/Met inhibitor, oncolytic. Drugs of the Future, 36(2), 91-98. https://doi.org/10.1358/dof.2011.036.02.1584112